Citations

Clear

2303 citation(s) found for "Yu, Edward".

Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer
Liu, Deli , Takhar, Mandeep, Alshalalfa, Mohammed , Erho, Nicholas , Shoag, Jonathan E. , Jenkins, Robert B. , Karnes, R. Jeffrey , Ross, Ashley E. , Schaeffer, Edward M. , Rubin, Mark A. , Klein, Eric A. , Tomlins, Scott A. , Spratt, Daniel E. , Spratt, Daniel E , Klein, Eric A , Trock, Bruce J , Den, Robert B. , Davicioni, Elai , Sboner, Andrea , Barbieri, Christopher , Rubin, Mark A

Mayo Clinic

JCO Precision Oncology | July 24, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-13

10.1200/po.18.00036 | PMID 30761387 Get It

Purpose Molecular characterization of prostate cancer, including The Cancer Genome Atlas, has revealed distinct subtypes with underlying genomic alterations. One of these core subtypes, SPOP (speckle-type POZ protein) mutant prostate cancer, has previously only been identifiable via DNA sequencing, which has made the impact on prognosis and routinely used risk stratification parameters unclear. Methods We have developed a novel gene expression signature, classifier (Subclass Predictor Based on Transcriptional Data), and decision tree to predict the SPOP mutant subclass from RNA gene expression data and classify common prostate cancer molecular subtypes. We then validated and further interrogated the association of prostate cancer molecular subtypes with pathologic and clinical outcomes in retrospective and prospective cohorts of 8,158 patients. Results The subclass predictor based on transcriptional data model showed high sensitivity and specificity in multiple cohorts across both RNA sequencing and microarray gene expression platforms. We predicted approximately 8% to 9% of cases to be SPOP mutant from both retrospective and prospective cohorts. We found that the SPOP mutant subclass was associated with lower frequency of positive margins, extraprostatic extension, and seminal vesicle invasion at prostatectomy; however, SPOP mutant cancers were associated with higher pretreatment serum prostate-specific antigen (PSA). The association between SPOP mutant status and higher PSA level was validated in three independent cohorts. Despite high pretreatment PSA, the SPOP mutant subtype was associated with a favorable prognosis with improved metastasis-free survival, particularly in patients with high-risk preoperative PSA levels. Conclusion Using a novel gene expression model and a decision tree algorithm to define prostate cancer molecular subclasses, we found that the SPOP mutant subclass is associated with higher preoperative PSA, less adverse pathologic features, and favorable prognosis. These findings suggest a paradigm in which the interpretation of common risk stratification parameters, particularly PSA, may be influenced by the underlying molecular subtype of prostate cancer.
CDKN2AGermline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations
Wieben, Eric D. , Chaffee, Kari G. , Antwi, Samuel O. , Olopade, Olufunmilayo I. , Li, Donghui , Highsmith, W. Edward, Colón‐Otero, Gerardo , Khanna, Lauren , Frucht, Harold, Blot, William J. , Wu, Lang , Almada, Luciana L. , Fernández-Zapico, Martín E. , Sicotte, Hugues , Pedersen, Katrina S. , Petersen, Gloria M. , Rabe, Kari G. , McWilliams, Robert R. , Raskin, Leon , Li, Donghui , Permuth, Jennifer B , Sicotte, Hugues , Antwi, Samuel O , Olopade, Olufunmilayo I , Pedersen, Katrina , Permuth, Jennifer B. , Olson, Janet E. , Genkinger, Jeanine M. , Zheng, Wei

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 23, 2018 | Volume: 27 | Issue: 11 | Pages: 1364-1370

10.1158/1055-9965.epi-17-1065 | PMID 30038052 Get It

AbstractBackground: Pathogenic germline mutations in the CDKN2A tumor suppressor gene are rare and associated with highly penetrant familial melanoma and pancreatic cancer in non-Hispanic whites (NHW). To date, the prevalence and impact of CDKN2A rare coding variants (RCV) in racial minority groups remain poorly characterized. We examined the role of CDKN2A RCVs on the risk of pancreatic cancer among minority subjects.Methods: We sequenced CDKN2A in 220 African American (AA) pancreatic cancer cases, 900 noncancer AA controls, and 183 Nigerian controls. RCV frequencies were determined for each group and compared with that of 1,537 NHW patients with pancreatic cancer. Odds ratios (OR) and 95% confidence intervals (CI) were calculated for both a case–case comparison of RCV frequencies in AAs versus NHWs, and case–control comparison between AA cases versus noncancer AA controls plus Nigerian controls. Smaller sets of Hispanic and Native American cases and controls also were sequenced.Results: One novel missense RCV and one novel frameshift RCV were found among AA patients: 400G>A and 258_278del. RCV carrier status was associated with increased risk of pancreatic cancer among AA cases (11/220; OR, 3.3; 95% CI, 1.5–7.1; P = 0.004) compared with AA and Nigerian controls (17/1,083). Further, AA cases had higher frequency of RCVs: 5.0% (OR, 13.4; 95% CI, 4.9–36.7; P < 0.001) compared with NHW cases (0.4%).Conclusions: CDKN2A RCVs are more common in AA than in NHW patients with pancreatic cancer and associated with moderately increased pancreatic cancer risk among AAs.Impact: RCVs in CDKN2A are frequent in AAs and are associated with risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev; 27(11); 1364–70. ©2018 AACR.
Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance)
Blarigan, Erin L. Van , Ou, Fang‐Shu , Niedzwiecki, Donna , Zhang, Sui , Fuchs, Charles S. , Ogino, Shuji , Benson, A.B., Hantel, Alexander, Atkins, James N., Giovannucci, Edward L. , Meyerhardt, Jeffrey A. , Saltz, Leonard , Ogino, Shuji , Meyerhardt, Jeffrey A , Ou, Fang-Shu , Niedzwiecki, Donna , Saltz, Leonard B. , Mayer, Robert J. , Venook, Alan P. , Song, Mingyang

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 23, 2018 | Volume: 27 | Issue: 10 | Pages: 1227-1230

10.1158/1055-9965.epi-18-0487 | PMID 30038051 Get It

Abstract Background: Higher intake of long-chain ω-3 polyunsaturated fatty acids and nuts, rich plant sources of unsaturated fats, after colon cancer diagnosis are associated with improved survival. It is not known whether the amount or the distribution of other types of fat is associated with survival after colon cancer. Methods: We prospectively examined postdiagnostic total, animal, and vegetable fats, as well as the saturated, monounsaturated, polyunsaturated, and trans fat in relation to disease-free survival among 1,011 patients with stage III colon cancer. Patients were enrolled between 1999 and 2001 at the onset of adjuvant chemotherapy and followed for recurrence or death through 2009. Results: During median follow-up of 7 years, we observed 305 deaths and 81 recurrences (total events: 386). Neither total nor any specific type of dietary fat examined was statistically significantly associated with risk of cancer recurrence or death from any cause (disease-free survival) after stage III colon cancer. Conclusions: The amount and type (animal, vegetable, saturated, monounsaturated, polyunsaturated, and trans) of dietary fat consumed after colon cancer does not appear to be substantially associated with risk of recurrence or survival. Impact: Neither total nor major types (animal, vegetable, saturated, monounsaturated, polyunsaturated, and trans) of dietary fat consumed after colon cancer was associated with cancer recurrence or survival. Cancer Epidemiol Biomarkers Prev; 27(10); 1227–30. ©2018 AACR.
Localized Structural Alterations Underlying a Subset of Unexplained Sudden Cardiac Death
Haı̈ssaguerre, Michel , Cheniti, Ghassen , Duchâteau, Josselin , Sacher, Frédéric , Puyo, Stéphane, Cochet, Hubert , Takigawa, Masateru , Denis, Arnaud , Martin, Ruairidh , Derval, Nicolas , Bordachar, Pierre , Ritter, Philippe , Ploux, Sylvain , Pambrun, Thomas , Klotz, Nicolas, Massoullié, Grégoire , Pillois, Xavier, Dallet, Corentin , Scouarnec, Solena, Ackerman, Michael J. , Tester, David J. , Piot, Olivier , Pasquié, Jean‐Luc , Leclerc, C, Hermida, Jean‐Sylvain , Maury, Philippe , Labrousse, Louis , Benoîst, David , Vigmond, Edward J. , Potse, Mark , Walton, Richard D. , Bernus, Olivier , Dubois, Rémi , Tester, David, Maury, Philippe , Haissaguerre, Michel , Hocini, Mélèze , Duchâteau, Josselin , Ploux, Sylvain , Schott, Jean‐Jacques , Scouarnec, Solena Le , Gandjbakhch, Estelle , Coronel, Ruben , Jaı̈s, Pierre , Nademanee, Koonlawee

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 12, 2018 | Volume: 11 | Issue: 7 | Pages: No page available

10.1161/circep.117.006120 | PMID 30002064 Get It

Background: Sudden cardiac death because of ventricular fibrillation (VF) is commonly unexplained in younger victims. Detailed electrophysiological mapping in such patients has not been reported. Methods: We evaluated 24 patients (29±13 years) who survived idiopathic VF. First, we used multielectrode body surface recordings to identify the drivers maintaining VF. Then, we analyzed electrograms in the driver regions using endocardial and epicardial catheter mapping during sinus rhythm. Established electrogram criteria were used to identify the presence of structural alterations. Results: VF occurred spontaneously in 3 patients and was induced in 16, whereas VF was noninducible in 5. VF mapping demonstrated reentrant and focal activities (87% versus 13%, respectively) in all. The activities were dominant in one ventricle in 9 patients, whereas they had biventricular distribution in others. During sinus rhythm areas of abnormal electrograms were identified in 15/24 patients (62.5%) revealing localized structural alterations: in the right ventricle in 11, the left ventricle in 1, and both in 3. They covered a limited surface (13±6 cm 2 ) representing 5±3% of the total surface and were recorded predominantly on the epicardium. Seventy-six percent of these areas were colocated with VF drivers ( P <0.001). In the 9 patients without structural alteration, we observed a high incidence of Purkinje triggers (7/9 versus 4/15, P =0.033). Catheter ablation resulted in arrhythmia-free outcome in 15/18 patients at 17±11 months follow-up. Conclusions: This study shows that localized structural alterations underlie a significant subset of previously unexplained sudden cardiac death. In the other subset, Purkinje electrical pathology seems as a dominant mechanism.
Improving Single-Nucleotide Polymorphism-Based Fetal Fraction Estimation of Maternal Plasma Circulating Cell-Free DNA Using Bayesian Hierarchical Models
Larson, Nicholas B. , Rowsey, Ross, Highsmith, W. Edward, Hoppman, Nicole L., Kocher, Jean‐Pierre , Klee, Eric W. , Na, Jie , Rowsey, Ross A, Highsmith, William Edward, Larson, Nicholas B , Wang, Chen

Mayo Clinic

Journal of Computational Biology | June 22, 2018 | Volume: 25 | Issue: 9 | Pages: 1040-1049

10.1089/cmb.2018.0056 | PMID 29932737 Get It

Comparison of Utilization of the Family and Medical Leave Act in Radiology Practices Between 2015 and 2016
Arleo, Elizabeth Kagan , Wolfman, Darcy J. , Parikh, Jay R. , Gridley, Daniel, Bender, Claire E., Bluth, Edward I. , Bender, Claire

Mayo Clinic

American Journal of Roentgenology | June 21, 2018 | Volume: 211 | Issue: 2 | Pages: 239-243

10.2214/ajr.17.19308 | PMID 29927327 Get It

Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis
Kotze, Paulo Gustavo , McKenna, Nicholas P. , Almutairdi, Abdulelah , Kaplan, Gilaad G. , Raffals, Laura E. , Loftus, Edward V. , Mckenna, Nicholas, Loftus, Edward V , Kotze, Paulo G , Kaplan, Gilaad G , Ma, Christopher , Panaccione, Remo , Lightner, Amy L. , McKenna, Nicholas P

Mayo Clinic

Therapeutic Advances in Gastroenterology | June 21, 2018 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/1756284818783614 | PMID 29977340 Get It

Background: Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn’s disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and perioperative safety in VDZ-treated patients undergoing nonintestinal operations. Methods: A case-matched study was performed at two inflammatory bowel disease (IBD) referral centers. Adult patients with CD and UC who underwent a nonintestinal surgical procedure during treatment with VDZ were included. Patients who had their last VDZ infusion up to 12 weeks before the procedure were considered exposed and were matched in a 1:1 ratio to patients without VDZ therapy, according to type of surgical procedure, age, and sex. The primary outcome was overall risk of early postoperative infectious complications (up to 30 days after surgery), readmissions, reoperations, surgical site infections, and other infections. The VDZ and control groups were subsequently compared using the Pearson χ2 test and Wilcoxon rank sum. Results: We identified 34 patients treated with VDZ who underwent 36 nonintestinal surgical procedures. These patients were matched with 36 control procedures. Postoperative complications were not different between the VDZ-treated and control cohorts for all outcomes analyzed: infectious complications occurred in 14% versus 8% ( p = 0.45), superficial surgical site infections 6% versus 0% ( p = 0.15), reoperations 6% versus 3% ( p = 0.56) and readmissions 11% versus 6% ( p = 0.37). Conclusions: VDZ-treated patients with IBD undergoing nonintestinal procedures did not have an increased risk of overall postoperative infections or other complications compared with matched controls.
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy
Chu, Edward , Allegra, Carmen J. , Tanigawara, Yusuke , Milano, G. , Diasio, Robert B. , Kim, Tae Won , Mathijssen, Ron H.J. , Muneoka, Katsuki, Diasio, Robert, Beumer, Jan Hendrik , Zhang, Li , Arnold, Dirk , Boku, Narikazu , Joerger, Markus

Mayo Clinic

Clinical Pharmacology & Therapeutics | June 20, 2018 | Volume: 105 | Issue: 3 | Pages: 598-613

10.1002/cpt.1124 | PMID 29923599 Get It

5‐Fluorouracil (5‐FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5‐FU therapy in patients with colorectal or head‐and‐neck cancer receiving common 5‐FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.